Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Healthpoint has initiated a clinical trial to evaluate the effectiveness of a widely prescribed enzymatic debriding agent on healing cutaneous wounds and resulting scars.
Subscribe to our email newsletter
The pilot study was prompted, in part, by clinical reports of the reduced incidence of hypertrophic scars and beneficial healing properties associated with Collagenase Santyl ointment.
The study is double-blind, site randomized and placebo controlled involving 30 healthy adult volunteers between the ages of 18 and 50. Site randomized means that each subject receives both active (Collagenase Santyl ointment) and placebo (white petrolatum ointment) with one test article applied to each of two dermatome-induced skin wounds according to the randomization scheme.
The study objectives are to compare the rate of complete wound closure within 21 days, and quality of resulting scar at three, six, and nine months, between the active and placebo treatments. The study is being conducted at the University of Texas Southwestern Medical Center in Dallas, with Shai Rozen serving as the principal investigator.
Robert Bancroft, general manager of Healthpoint, said: “This study is another example of Healthpoint’s ongoing commitment to scientific evaluation and clinical research designed to provide healthcare professionals with evidence-based therapies that contribute to improved clinical and quality of life outcomes.”